In a nutshell This study investigated the effects of adding ixazomib (Ninlaro) to lenalidomide (Revlimid) and dexamethasone (Dexasone) for patients with unresponsive multiple myeloma. The main finding was that patients receiving ixazomib plus lenalidomide and dexamethasone survived longer without worsening of cancer (progression-free...
Read MoreWhat is the benefit of adding ixazomib to lenalidomide and dexamethasone for relapsing/refractory multiple myeloma?
